Over 100 patients with advanced
refractory cancer received CTLA-4 and/or PD-1.
The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines was held in 2017 to address the issue of
refractory cancer pain and minimally invasive treatment such as intrathecal pump implantation [1], and Manuel Julia et al.
"Our new innovative translational research platform, the AVATAR platform, based on AVATAR Mouse(R) and AVATASCAN(R) was developed with strong support from the Korean government's Ministry of Health and Welfare to provide treatment solutions for
refractory cancer patients.
Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for
refractory cancer pain: impact on pain, drug-related toxicity, and survival.
Coverage includes the need for a specialized interest combining palliative care and nutrition; general concepts; personal perspectives; quality of life in the young and adults; the world's major religions' views on end-of-life issues; Japanese, Chinese, and Indian perspectives; forgoing of tube feeding; artificial nutrition; gastrointestinal side effects and symptoms; gastrojejunostomy; withholding or withdrawing nutritional support; vitamin deficiency; hydration; dysphasia; appetite loss; fatigue; taste and smell alterations; nausea;
refractory cancer cachexia; head and neck cancer; the vegetative state; renal failure; end-stage liver disease; motor disease; effects of steroids; and appetite stimulants.
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) has announced the presentation of the overall survival results from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against
Refractory Cancer).
Parents of a child with
refractory cancer can become desperate when seeking an effective therapy.
The Satraplatin and Prednisone Against
Refractory Cancer (SPARC) trial randomly assigned a total of 950 men with advanced prostate cancer in a 2:1 fashion to satraplatin (80 mg/[m.sup.2] per day for 5 days) plus prednisone or the same regimen of placebo plus prednisone.
-- A novel pain drug from puffer fish poison showed an analgesic effect that lasted up to 2 weeks following intramuscular injection in patients with
refractory cancer pain, Dr.
M2 PHARMA-March 6, 2019-NKMax America wins US FDA approval of IND for SNK01 treatment for patients with
refractory cancerGlobal Banking News-March 6, 2019-NKMax America wins US FDA approval of IND for SNK01 treatment for patients with
refractory cancer